Elotuzumab
Ixazomib
Daratumumab (MM)
Carfilzomib
NCCN Guidelines for Patients: Multiple Myeloma
International Myeloma Foundation (IMF)
National Cancer Institute (NCI) - Supported Cancer Clinical Trials
The Leukemia and Lymphoma Society